Lixiana

This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Latest news

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for
Daiichi Sankyo cuts a swathe through US workforce

The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as
Daiichi Sankyo licenses clot-busting antibody

The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE recommends Daiichi Sankyo's Lixiana for DVT and PE. Institute's final guidance concludes the novel oral anticoagulant is cost effective. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better
Daiichi’s new anticoagulant recommended by NICE

Daiichi’ s new anticoagulant recommended by NICE. Lixiana nears NHS funding approval for certain patients with atrial fibrillation. ... NICE has already recommended Lixiana for the treatment of deep vein thrombosis and pulmonary embolism, and

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager: Negotiable

Senior Training Manager - Surrey: Competitive Salary &Bonus

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager- 4 days per week or full-time: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Systematic Review Lead- London: Negotiable

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Associate Scientific Director: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Healthcare PR Senior Account Manager: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...